Vivani Medical, Inc.
No enriched coverage for $VANI in the last 7 days.
No SEC Form 4 filings for $VANI in the last 30 days.
See all $VANI insider activity →Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana
Williams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.
Vivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. The companies noted no exclusivity. Vivani expects to start a Phase 1 first-in-human trial in mid-2026, comparing with Wegovy, to support a Phase 2 dose-ranging study.
Recent VANI coverage spans financial news, insider activity and corporate actions.
Near-term catalyst is November 2026 SLIM-1 top-line data, with additional optionality from a Novo Nordisk non-exclusive evaluation agreement and a planned Cortigent spin/merger financing path.
The filing is a primary-source insider purchase, but it is not accompanied by new company fundamentals or guidance.
The Novo Nordisk evaluation agreement and planned first-in-human Phase 1 start are incremental but tangible catalysts for Vivani’s GLP-1 implant program.
The Novo Nordisk evaluation agreement is a meaningful validation step for Vivani’s semaglutide implant program and NanoPortal platform.
Deal enables Novo Nordisk evaluation of Vivani’s lead semaglutide implant, supporting near-term validation and potential partnering optionality.
alphai scores every news story that mentions VANI with an AI model for sentiment and relevance, and aggregates insider trades from Vivani Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Vivani Medical, Inc. (VANI) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Vivani Medical Reports Second Quarter 2026 Financial Results and Provides Business Update All participants successfully dosed in SLIM-1™, the Company's first-in-human Phase 1 trial of NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight mana
7 min readWilliams Gregg purchased 793,650 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($1.00M total) on 2026-07-15.
2 min readVivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. The companies noted no exclusivity. Vivani expects to start a Phase 1 first-in-human trial in mid-2026, comparing with Wegovy, to support a Phase 2 dose-ranging study.
3 min readVivani Medical (NASDAQ: VANI) said it signed an agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139 semaglutide implant using Vivani’s NanoPortal platform for chronic weight management. Vivani noted no exclusivity. It plans to start a Phase 1 first-in-human study mid-2026, using Wegovy as comparator, to support a Phase 2 dose-ranging study.
2 min readVivani Medical (Nasdaq: VANI) said it signed a non-exclusive agreement with Novo Nordisk to let Novo evaluate Vivani’s NPM-139, a miniature, ultra long-acting semaglutide implant for chronic weight management. Vivani expects to start a Phase 1 first-in-human trial of NPM-139 mid-2026, using Wegovy as an active comparator.
4 min readVivani Medical, Inc. (VANI) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. EX-2.1 7 ex21_1.htm EXHIBIT 2.1 Exhibit 2.1 AGREEMENT AND PLAN OF MERGER BY AND AMONG CLEARONE INC., CLRO MERGER SUB, INC., CORTIGENT, INC. AND VIVANI MEDICAL, INC. Dated as of July 1, 2026 TABLE OF CONTENTS Page ARTICLE 1 DESCRIPTION OF TRANSACTION 2 1.1 Structure of the Merger
2 min readVivani Medical’s subsidiary Cortigent will merge with ClearOne, with ClearOne renamed Cortigent Holdings and expected to trade on Nasdaq under ticker CRGT. ClearOne will raise $10M–$15M via concurrent financing. Vivani will receive 12.5M shares and is expected to own 59.4%–67.5% of the combined company; former ClearOne holders 12.7%–14.4%.
4 min readVivani Medical (Nasdaq: VANI) said its subsidiary Cortigent will merge into ClearOne (Nasdaq: CLRO) via a definitive agreement, making Cortigent a wholly owned ClearOne unit. ClearOne plans a concurrent $10m–$15m financing. Vivani will receive 12.5m ClearOne shares and own 59.4%–67.5%; the combined company will trade as CRGT, expected to close Q3 2026.
5 min readVivani Medical, Inc. (VANI) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.1 7 ex101_1.htm EXHIBIT 10.1 Exhibit 10.1 VIVANI MEDICAL, INC. AMENDED AND RESTATED 2022 OMNIBUS INCENTIVE PLAN SECTION 1. GENERAL PURPOSE OF THE PLAN; DEFINITIONS The name of the plan is the Amended and Restated Vivani Medical, Inc. 2022 Omnibus Incentive Plan (the “Plan”)
2 min readWilliams Gregg purchased 1,587,301 indirectly-held shares of Vivani Medical, Inc. (VANI) at $1.26 ($2.00M total) on 2026-06-15.
1 min read
